New Diabetes Drug Enters Phase 2a Pilot Study
The trial tests a new drug in adults with Type 1 diabetes who use automated insulin delivery systems.
Updated on Oct. 27, 2026 in Diabetes
Live Poll
Is now a good time to participate in experimental clinical trials for chronic condition treatments?
vTv Therapeutics has begun a Phase 2a pilot study to test the efficacy of cadisegliatin in adults with Type 1 diabetes. The trial assesses how this experimental medication functions when used alongside hybrid closed-loop insulin systems.
Why it matters
Researchers are investigating if this medication can improve glycemic control and lower hypoglycemia risks for the 2.1 million Americans living with Type 1 diabetes. This study aims to provide critical data on using the drug with current automated insulin delivery technology.
This Phase 2a randomized, double-blind, placebo-controlled crossover study involves 40 adults with Type 1 diabetes using hybrid closed-loop systems. The trial measures glycemic control over a six-week treatment period, though results remain preliminary.
The players
vTv Therapeutics
A High Point-based biotechnology company focused on developing therapies for metabolic diseases.
FDA
The federal agency responsible for overseeing clinical drug trials and granting Breakthrough Therapy designations.
The details
Cadisegliatin is a liver-selective small molecule designed to act as a glucokinase activator to potentially improve glucose regulation. The study uses mixed-meal tolerance tests to observe postprandial glucose excursions in participants who have used hybrid insulin delivery systems for at least three months. By comparing the drug against a placebo, researchers aim to determine its impact on maintaining target A1C levels when combined with existing automated insulin delivery devices.
Timeline
October 27, 2026: First participant randomized in the Phase 2a study.
October 2026: Enrollment completed for the separate Phase 3 CATT1 study.
Health Landscape
This trial represents a shift toward integrating novel pharmacological agents with modern automated insulin delivery systems. It follows the broader research arc of the CATT1 clinical study program, which seeks to refine treatment options for the Type 1 diabetes population.
This study is currently recruiting a limited group of 40 participants, meaning it is not yet a broad clinical option for the public. If you use a hybrid closed-loop insulin system, discuss whether such research trials might be appropriate for your specific health history with your endocrinologist.
The takeaway
While this pilot trial explores new treatment avenues for Type 1 diabetes, it remains in the early stages of investigation. Patients interested in emerging therapies should track updates on FDA-designated treatments through their regular endocrinology appointments.
Further reading
For more information on managing the condition, visit Diabetes.
More information
Review the full Phase 2a clinical trial details on the official government registry.
Source note: This article includes information reported by The Manila times.
Live Poll
Is now a good time to participate in experimental clinical trials for chronic condition treatments?
